Table 1.
ADCs in development for triple-negative breast cancer.
| Name | ADC target | Drug class/target | Latest development stage | Sponsor/trial ID |
|---|---|---|---|---|
| Sacituzumab govitecan IMMU-132 | Trophoblast cell surface antigen 2 (TROP2) | Irinotecan/topoisomerase I | Metastatic TNBC Phase III |
Immunomedics NCT02574455 |
| Glembatumumab vedotin CDX-011 CR011-vc-MMAE | Glycoprotein nonmetastatic b (GPNMB) | Auristatin/tubulin | Metastatic TNBC Phase II |
Celldex Therapeutics NCT01997333 |
| SAR566658 anti-CA6-DM4 | CA6 sialoglycotope of MUC1 | Maytansinoid/tubulin | Metastatic TNBC Phase II |
Sanofi NCT02984683 |
Abbreviations: ADC, antibody-drug conjugate; TNBC, triple-negative breast cancer.